AstraZeneca touts arthritis, lupus data with a rosy view of its pipeline

Damian Garde Two key investigational drugs came through in mid-stage studies, providing some ballast for the drugmaker as it boasts the value of its pipeline in an effort to ward off ...

Endo appoints former Bausch + Lomb exec to head corporate strategy

Alok Saboo FierceBiotech News

Regeneron R&D chief’s compensation shrinks, but still tops the chart

John Carroll FierceBiotech News

BMS extends deal with Samsung as its pipeline percolates with more biologics

Eric Palmer With a host of biologic products in its pipeline, Bristol-Myers Squibb sees the need for more capacity for making large-molecule drugs and has decided to build on a relationship ...

GSK and Novartis reshape EU biotech, Celgene and Hyperion in Euro deals, U.K. cell therapy grows

Nick Paul Taylor In the latest edition of our weekly EuroBiotech Report, the card shuffling at GlaxoSmithKline and Novartis is raising questions about the future of several companies. ...

GSK’s R&D staff hit with trade rumors spurred by Novartis’ cancer pact

John Carroll GlaxoSmithKline hasn't spelled out exactly how its big deal with Novartis will impact individual workers. But the rumor mill has it that more than 100 investigators ...

Lupin recalls more Suprax on purity problems, adding to Indian pharma’s quality questions

Tracy Staton In the latest black eye for India's pharma industry, Lupin is recalling some 10,000 bottles of its Suprax antibiotic in the U.S. The pills fell short of standards for ...

Chimerix CEO Moch steps down after compassionate-use controversy

Alok Saboo FierceBiotech News

Reckitt may top Novartis, Sanofi in $12B race for Merck consumer unit

Tracy Staton With a final bid deadline looming, Merck & Co.'s consumer health unit still has several big-name pharma suitors. But Reckitt Benckiser, the Irish consumer specialist, ...

Twitter praises Boehringer for social media savvy

Carly Helfand Which pharma companies are getting it right when it comes to social media? As far as Twitter is concerned, Boehringer Ingelheim is up there. FiercePharma News

GlaxoSmithKline eyes rare disease to widen its respiratory lead

Damian Garde GlaxoSmithKline is looking to deepen its respiratory pipeline with another late-stage trial of the injectable mepolizumab, this time studying the drug's effects in ...

CFR and Adcock Ingram give up on their transcontinental merger

Eric Palmer The planned transcontinental marriage between South America's CFR and South Africa's Adcock Ingram had been on shaky grounds for some time. But the engagement has ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS